Skip to main content

Colorectal cancer risk in patients with inflammatory bowel disease and Lynch syndrome


Chronic inflammatory bowel disease (IBD) and Lynch syndrome (LS) are associated with an increased risk for developing colorectal cancer (CRC). After 8-10 years of pan-ulcerative colitis (DC), the risk of CRC is 2%, increasing by 0.5-1.0% annually. LS has been associated with a 60-80% lifetime risk of CRC. It is unclear whether individuals diagnosed with both IBD and LS would have a cumulative risk or earlier age of onset of CRC based on their diagnoses.


Patients with IBD and a germline mismatch repair gene (MMR) mutation were identified through the Familial Gastrointestinal Cancer Registry at Mount Sinai Hospital in Toronto, Canada. Information on their IBD diagnosis, colorectal screening/surgery, medication use, family history and genetic test results were collected (Table 1).

Table 1 Table 1


Five of 329 (1.5%) individuals with germline MMR mutations reported having a history of IBD.


Concurrent IBD and LS did not appear to predispose to early-onset CRC in our small case series.

Author information



Corresponding author

Correspondence to Melyssa Aronson.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Aronson, M., Stempak, J., Silverberg, M. et al. Colorectal cancer risk in patients with inflammatory bowel disease and Lynch syndrome. Hered Cancer Clin Pract 8, P1 (2010).

Download citation


  • Colorectal Cancer
  • Inflammatory Bowel Disease
  • Lynch Syndrome
  • Small Case Series
  • Genetic Test Result